Skip to content

Public FDA record

Z-1039-2017: AFX Endovascular AAA System, Endoleak Type: IIIB Common Name: AFX Bifurcated and Accessory Stent Grafts

Recall record Z-1039-2017 for Endologix. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1039-2017
Company in FDA record
Endologix
FDA classification date
Jan 19, 2017
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Endologix updated the Instructions for Use (IFU) and implemented modifications to the AFX Endovascular AAA System (AFX System).

Source facts

Action
Endologix sent a Dear Phycisicans Letter dated June 2, 2015, to all affected customers to inform them of the enclosed 2014 Clinical Update on the Endologix Endovascular Systems for AAA Repair. The letter informs the customers of the update reports the cumulative clinical data and information on the Powerlink System and the AFX Endovascular AAA System (AFX System). On January 2016, a Dear Physician letter was sent to inform the customers of the 2015 Clinical Update covering the Endologix Endovascular Systems for AAA Repair. Customers were informed the update reports the cumulative clinical data and commercial experience (i.e., post-market surveillance) of the Powerlink System and the AFX Endovascular AAA system and contains important information and recommendations regarding the continued safe and effective use of these devices. On 12/27/16, a Dear Physician letter was sent to inform customers of the important information related to the AFX Endovascular AAA System (AFX System). The letter informs the customers of a series of updates to the Instructions for Use (IFU) and modifications to the product were implemented, including introduction of a graft material processing improvement known as Duraply. The letter informs the customers that at the time of the submission of these modifications to FDA, they were not identified as measures intended to address Type III endoleaks. The on-going Endologix investigation has determined that these changes may help prevent the occurrence of Type III endoleaks reported with the AFX device. Customers with any questions are instructed to contact their Endologix representative.
Initiated
2016-12-27
Root cause
Device Design
Terminated
2017-04-28
Distribution
Worldwide Distribution - US (nationwide) and Internationally to Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, and United Kingdom.
Recall number
Z-1039-2017
Recall status
Terminated
CDRH record ID
152176
FDA classified
2017-01-19
Recall event number
76113

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗